erlotinib hydrochloride has been researched along with Hypertension, Pulmonary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hohenforst-Schmidt, W; Huang, H; Kakolyris, S; Kioumis, I; Lampaki, S; Li, Q; Organtzis, J; Papaiwannou, A; Petridis, D; Pitsiou, G; Porpodis, K; Syrigos, K; Tsiouda, T; Turner, JF; Zarogoulidis, K; Zarogoulidis, P | 1 |
| Banat, GA; Cornitescu, T; Dahal, BK; Dumitrascu, R; Ghofrani, HA; Grimminger, F; Kosanovic, D; Pullamsetti, SS; Schermuly, RT; Seeger, W; Tretyn, A; Voswinckel, R; Weissmann, N | 1 |
2 other study(ies) available for erlotinib hydrochloride and Hypertension, Pulmonary
| Article | Year |
|---|---|
Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment.
Topics: Administration, Inhalation; Benzamides; Erlotinib Hydrochloride; Gefitinib; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2014 |
Role of epidermal growth factor inhibition in experimental pulmonary hypertension.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; Hypertension, Pulmonary; Lapatinib; Male; Mice; Muscle, Smooth, Vascular; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pulmonary Wedge Pressure; Quinazolines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Vascular Resistance | 2010 |